Diana Cervantes-Madrid | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/diana-cervantes-madrid/Diana Cervantes-MadridHugo Blox Builder (https://hugoblox.com)en-usWed, 18 Dec 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngDiana Cervantes-Madridhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/diana-cervantes-madrid/Repotrectinib (TPX-0005) effectively reduces growth of ALK-driven neuroblastoma cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Wed, 18 Dec 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/repotrectinib/Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cellshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Tue, 01 Jan 2019 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alectinib_neuroblastoma/Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathwayshttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/Tue, 20 Nov 2018 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/phosphoproteome_alk/MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomashttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/Tue, 28 Nov 2017 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/trametinib_alk/